Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles B Hicks

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Antimicrobial Agents and Chemotherapy|July 18, 2002
Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysisPaul R Bohjanen, Melissa D Johnson, Lynda A Szczech, et al.
Archives of Internal Medicine|September 25, 2003
Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settingsAmy C Weintrob, Julieta Giner, Prema Menezes, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2009
HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infectionMattia Bonsignori, M Anthony Moody, Robert J Parks, et al.
Journal of Clinical Immunology|September 15, 2005
Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus functionGregory D Sempowski, Charles B Hicks, Joseph J Eron, et al.
AIDS Research and Human Retroviruses|January 25, 2005
Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordanceSusan S Kaplan, Guido Ferrari, Terri Wrin, et al.
Lancet (London, England)|August 8, 2006
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trialsCharles B Hicks, Pedro Cahn, David A Cooper, et al.
Journal of Virology|September 29, 2004
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1Kimberly Ritola, Christopher D Pilcher, Susan A Fiscus, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 31, 2012
CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infectionMarc A Frahm, Ralph A Picking, JoAnn D Kuruc, et al.
Plos One|June 30, 2017
Diminished physical function in older HIV-infected adults in the Southeastern U.S. despite successful antiretroviral therapyAudrey L Khoury, Miriam C Morey, Tammy C Wong, et al.
AIDS (London, England)|September 23, 2003
Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infectionStephanie A Freel, Susan A Fiscus, Christopher D Pilcher, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|July 18, 2002
Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysisPaul R Bohjanen, Melissa D Johnson, Lynda A Szczech, et al.
Archives of Internal Medicine|September 25, 2003
Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settingsAmy C Weintrob, Julieta Giner, Prema Menezes, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 24, 2009
HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infectionMattia Bonsignori, M Anthony Moody, Robert J Parks, et al.
Journal of Clinical Immunology|September 15, 2005
Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus functionGregory D Sempowski, Charles B Hicks, Joseph J Eron, et al.
AIDS Research and Human Retroviruses|January 25, 2005
Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordanceSusan S Kaplan, Guido Ferrari, Terri Wrin, et al.
Lancet (London, England)|August 8, 2006
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trialsCharles B Hicks, Pedro Cahn, David A Cooper, et al.
Journal of Virology|September 29, 2004
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1Kimberly Ritola, Christopher D Pilcher, Susan A Fiscus, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 31, 2012
CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infectionMarc A Frahm, Ralph A Picking, JoAnn D Kuruc, et al.
Plos One|June 30, 2017
Diminished physical function in older HIV-infected adults in the Southeastern U.S. despite successful antiretroviral therapyAudrey L Khoury, Miriam C Morey, Tammy C Wong, et al.
AIDS (London, England)|September 23, 2003
Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infectionStephanie A Freel, Susan A Fiscus, Christopher D Pilcher, et al.
Pageof 9